1. Medtech Insight
  2. >>Policy & Regulation

Top Medtech Lobbyist Doubts Legislative Repercussions Of New Netflix Documentary

AdvaMed's top lobbyist says a new documentary critical of the medical device industry and US FDA's device review pathways is unlikely to result in Congressional action. However, the group is talking to members on Capitol Hill to make sure they fully understand the context within which devices are reviewed and marketed.

Netflix Bleeding Edge documentary screen shot of Scott Whitaker
AdvaMed CEO Scott Whitaker was featured in a new Netflix documentary on how medical devices come to the US market

A new Netflix documentary by Oscar-nominated director Kirby Dick is highly critical of the medical device industry and US FDA. While the film is receiving acclaim and attention, the top lobbyist at AdvaMed says it's nothing but an "entertainment piece" and a "hit job" that misleads viewers about how products get to market.

The documentary, "The Bleeding Edge," looks at how devices are regulated in the US. It showcases examples such as Bayer AG's Essure contraceptive device, which was recently yanked from...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 
• By Amanda Maxwell

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.